Newsroom

Ellegaard Göttingen Minipigs Enters into a License and Commercialization Agreement for Göttingen Minipigs Research Models in Partnership with Exemplar Genetics

Dalmose, Denmark, 26 November 2018

Ellegaard Göttingen Minipigs A/S, today announced the signing of a license and commercialization agreement with Exemplar Genetics to develop and commercialize genetically modified Göttingen Minipigs models of human disease on a target-by-target basis. Göttingen Minipigs are a small, docile, microbiologically and genetically well-defined large animal model recognized by the global biomedical research community and regulatory authorities, making Göttingen Minipigs the genetics of choice for preclinical studies.

H19 Induces Abdominal Aortic Aneurysm Development and Progression

Original research article published on April 18, 2018 in Circulation.

DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.032184 Circulation. 2018;CIRCULATIONAHA.117.032184

Download PDF from Circulation here

Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use

SIOUX CENTER, Iowa, April 16, 2018

A MiniSwine Genetic Model of Hypertrophic Cardiomyopathy

July 10–13, 2017 - BCVS Scientific Sessions 2017

Exemplar Genetics presented an Oral Abstract at the BCVS Scientific Sessions in Portland, Oregon titled "A MiniSwine Genetic Model of Hypertrophic Cardiomyopathy". Review the abstract in its entirety here

Swart wins Cultivation Corridor award

Wednesday, March 22, 2017 10:45 AM

John Swart, founder and president of Exemplar Genetics, won this year's Cultivation Corridor Iowa Biotech Leadership Award, which recognizes leadership, innovation, advocacy and commitment in the biotech industry. Swart founded the company in 2008 in Sioux Center to develop specialized miniature swine models that exhibit human disease states to help test whether medications and devices work. Former Monsanto executive Ted Crosbie, who died last year, also was recognized for his contributions to the industry.

Exemplar Genetics Awarded Subcontract to Advance New Therapeutic Models for Sickle Cell Disease

Download the full release here

Clinical Data from Phase 1 SAD Trials of MYK-461 in Hypertrophic Cardiomyopathy Patients and Healthy Volunteers

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2016

Read the full release here

Exemplar Genetics ExeGen Cystic Fibrosis Research Model Utilized in Development of New Gene Therapy Treatments

Sioux Center, IA - September 13, 2016

Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publication in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen^® CFTR MiniSwine research models to help define and develop effective gene therapies for cystic fibrosis.

Game-Changing Animal Research Models Offer Superior Translational Research and Better Predictive Efficacy

SIOUX CENTER, Iowa, April 27, 2016

Read the full article here

First Genetically Engineered Miniswine Research Model Cleared by FDA for Commercial Use

The Growth of Iowa Biotech

By Jenny Rood | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

Search form

Newsroom

Pages